Stockscreener 앱 받기
9.76
2.41%
0.23
Atara Biotherapeutics Inc 주식(ATRA)의 최신 뉴스
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Independent Director of Atara Biotherapeutics Picks Up 272% More Stock - simplywall.st
Atara Biotherapeutics (ATRA) Director Brian Cherry Buys 104,166 Shares - GuruFocus
Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares - Investing.com Canada
Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares By Investing.com - Investing.com South Africa
Atara Biotherapeutics Director Purchased Shares Worth Over $999K - TradingView
(ATRA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
ATRA Shareholders Have Opportunity to Lead Atara Biotherapeutics - The National Law Review
Atara Biotherapeutics director Brian Cherry acquires 104,166 common shares for $999,993.60 - Bitget
Atara Biotherapeutics president and CEO sells $40,882 in shares - Investing.com India
Atara Biotherapeutics (ATRA) employee plans 5,062-share tax sale - stocktitan.net
Atara (ATRA) Results Breakdown: Profit Per Share Surpasses Its Benchmark on the Day; Post-Report Move: The Stock Records a 1.26% Increase at the CloseProfit Growth Outlook - vinanet.vn
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Atara Biotherapeutics (NASDAQ:ATRA) Rating Increased to Hold at Wall Street Zen - MarketBeat
Why (ATRA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Atara Biotherapeutics (ATRA): Point72 entities report 7.6% beneficial stake - Stock Titan
Atara Biotherapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | ATRA | US0465132068 - marketscreener.com
Atara Biotherapeutics Inc earnings missed by $0.10, revenue fell short of estimates - Investing.com Nigeria
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress - BioSpace
Atara Biotherapeutics cuts costs 87%, extends cash runway to mid-2027 - scanx.trade
Is Atara Biotherapeutics Inc (ATRA) Positioned for Growth After - GuruFocus
Atara Biotherapeutics (NASDAQ:ATRA) Announces Quarterly Earnings Results - MarketBeat
Atara Biotherapeutics 2Q 2026: Revenue $0.63M, Net loss $(9.0)M — 10-Q Summary - TradingView
Atara Biotherapeutics: Q2 Earnings Snapshot - AOL.com
BRIEF-Atara Biotherapeutics Q2 EPS USD -0.32 - TradingView
Atara Biotherapeutics (ATRA) Rallies 3.8% to $8.94, Approaching Resistance at $9.39Volume Nodes - dars.gov.et
Atara Biotherapeutics (NASDAQ:ATRA): What Could Today’s Update Reveal About Program Focus And Funding Discipline? - Kalkine Media
ATRA DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds - The National Law Review
Atara Biotherapeutics (NASDAQ:ATRA) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Atara Biotherapeutics Inc (ATRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Atara Biotherapeutics, Inc. expected to post a loss of 31 cents a shareEarnings Preview - TradingView
ATRA Q2'26 Earnings: EPS estimate is (0.32) USD - TradingView
ATRA DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC - The National Law Review
Understanding Momentum Shifts in (ATRA) - Stock Traders Daily
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
ATRA Q2'26 Earnings: revenue estimate is 550.00K USD - TradingView
Atara Biotherapeutics (ATRA) Projected to Release Earnings on Monday - MarketBeat
Enterprise value to revenue forward of Atara Biotherapeutics, Inc. – NASDAQ:ATRA - TradingView
Atara Biotherapeutics Inc (ATRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
EcoR1 Capital LLC Sells 473,590 Shares of Atara Biotherapeutics, Inc. $ATRA - MarketBeat
Atara Biotherapeutics Inc (ATRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atara Biotherapeutics Inc (ATRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Atara Biotherapeutics Inc (ATRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Atara Biotherapeutics Inc (ATRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Form 13D/A Atara Biotherapeutics For: 24 July By Investing.com - Investing.com South Africa
Atara Biotherapeutics Inc (ATRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Form 4 Atara Biotherapeutics Inc For: 24 July By Investing.com - Investing.com Nigeria
Atara Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:ATRA - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect - ACCESS Newswire
Form 13D/A Atara Biotherapeutics For: 24 July - Investing.com India
Redmile adjusts Atara Biotherapeutics (ATRA) ownership after warrant exercises - Stock Titan
ATRA|Atara Biotherapeutics Inc|Price:7.559|Chg%:-0.151 - TradingKey
Atara Biotherapeutics Inc (ATRA) Cash Flow - TradingKey
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Price to book forward of Atara Biotherapeutics, Inc. – NASDAQ:ATRA - TradingView
Avoiding Lag: Real-Time Signals in (ATRA) Movement - Stock Traders Daily
Atara Biotherapeutics (NASDAQ:ATRA) Share Price Passes Below 50-Day Moving AverageShould You Sell? - MarketBeat
0.86%
0.31%
자본화:
|
볼륨(24시간):